Skip to main content
SpringerLink
Log in

The clinical significance of HAMA in patients treated with mouse monoclonal antibodies

  • Published:
Cell Biophysics Aims and scope Submit manuscript

Abstract

Twenty-four patients were analyzed for the development of HAMA (human antimouse antibodies) after being treated with repeated doses (200–500 mg) of the mouse monoclonal antibody (MAb) 17-1A. All patients developed anti-17-1A IgG antibodies, and most of them also developed IgM antibodies. In only two patients could immune complexes be demonstrated. Allergic reactions were rare (1.9%). In an extended study, a further 19 patient were analyzed for an idiotypic response. Forty-one out of 43 patients developed antiidiotypic antibodies (ab2), and 20 of these also antianti-idiotypic antibodies (ab3). Ab3 + patients responded significantly better (p=0.01) and survived longer (p<0.001) compared to ab3 − patients. In this study, we showed that MAb 17-1A could be repeatedly given on a safe basis. The development of high titers of HAMA did not cause significant clinical problems when further repeated infusions of MAb 17-1A were given. The development of an idiotypic response also indicate that the induction of HAMA might be beneficial and not harmful to the patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stewart, J. S., Hird, V., Snook, D., Sullivan, M., Hooker, G., Courtenay-Luck, N., Sivolapenko, G., Griffiths, M., Myers, M. J., Lambert, H. E., Munro, A. J., and Epenetos, A. A. (1989) Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies.Int. J. Rad. Oncol. Biol. Phys. 16, 405–413.

    CAS  Google Scholar 

  2. v. Wussow, P., Spitler, L., Block, B., and Deicher, H. (1988) Immunotherapy in patients with advanced malignant melanoma using a monoclonal antimelanoma antibody Ricin A immunotoxin.Eur. J. Cancer Clin. Oncol. 24, S69-S73.

    Article  Google Scholar 

  3. Steplewski, Z. (1986) Wistar symposium on immunodiagnosis and immunotherapy with CO17-1A MAb in gastroinstestinal cancer.Hybridoma 5(Suppl. 1) S1-S186.

    Google Scholar 

  4. Vadhan-Raj, S., Cordon-Cardo, C., Carswell, E., Mintzer, D., Dantis, L., Duteau, C., Templeton, M. A., Oettgen, H. F., Old, L. J., and Houghton, A. N. (1988) Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites.J. Clin. Oncol. 6, 1636–1648.

    PubMed  CAS  Google Scholar 

  5. Jerne, N. K. (1974) Towards a network theory of the immune system.Ann. Immunol. 125, 373–389.

    CAS  Google Scholar 

  6. Traub, U. C., DeJager, R. L., Primus, F. J., Losman, M., and Goldenberg, D. M. (1988) Antiidiotype antibodies in cancer patients receiving monoclonal antibody to carcinoembryonic antigen.Cancer Res. 48, 4002–4006.

    PubMed  CAS  Google Scholar 

  7. Herlyn, D., Sears, H., Iliopoulos, D., Lubeck, M., Doujllard, J.-Y., Sindelar, W., Tempero, M., Mellstedt, H., Maher, M., and Koprowski, H. (1986) Antiidiotypic antibodies to monoclonal antibody CO17-1A.Hybridoma 5(Suppl. 1) 51–58.

    Google Scholar 

  8. Koprowski, H., Herlyn, D., Lubeck, M., DeFreitas, E., and Sears, F. (1984) Human anti-idiotype antibodies in cancer patients: is the modulation of the immune response beneficial for the patient?.Proc. Natl. Acad. Sci. USA 81, 216–219.

    Article  PubMed  CAS  Google Scholar 

  9. Steinitz, M., Tamir, S., Frodin, J.-E., and Mellstedt, H. (1988) Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies.J. Immunol. 141, 3516–3522.

    PubMed  CAS  Google Scholar 

  10. Courtenay-Luck, N. S., Epenetos, A. A., Sivalapenko, G. B., Barkans, J. R., Larche, M., and Ritter, M. A. (1988) Development of anti-idiotypic antibodies against tumor antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies.Lancet ii, 894–897.

    Article  Google Scholar 

  11. Wettendorf, M., Iliopoulos, D., Tempero, M., Kay, D., DeFreitas, E., Koprowski, H., and Herlyn, D. (1989) Idiotypic cascades in cancer patients treated with monoclonal antibody CO17-1A.Proc. Natl. Acad. Sci. USA 86, 3787–3791.

    Article  Google Scholar 

  12. Mellstedt, H., Frodin, J-E., Masucci, G., Ragnhammar, P., Fagerberg, J., Hjelm, A.-L., Sheyte, J., Wersäll, P., and Östeborg, A. (1991) The therapeutic use of monoclonal antibodies in colorectal carcinoma.Semin. Oncol. 18, 462–477.

    PubMed  CAS  Google Scholar 

  13. Sears, H. F., Herlyn, D., Herlyn, M., Grotzinger, P. J., Steplewski, Z., Gerhard, W., and Koprowski, H. (1981) Ex vivo perfusion of a tumor-containing-colon with monoclonal antibody.J. Surg. Res. 31, 145–150.

    Article  PubMed  CAS  Google Scholar 

  14. Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., and Fuhrer, P. (1979) Colorectal carcinoma antigens detected by hybridoma antibodies.Somat. Cell Genet. 5, 957–971.

    Article  PubMed  CAS  Google Scholar 

  15. Frödin, J.-E., Pihlstedt, P., Lefvert, A.-K., and Mellstedt, H. (1987) Isolation and characterization of autologous blood mononuclear cells used for auto-infusion together with monoclonal antibodies in tumor treatment.Hybridoma 6, 655–664.

    Article  Google Scholar 

  16. Frödin, J.-E., Faxas, M.-E., Hagström, B., Lefvert, A.-K., Masucci, G., Nilsson, B., Steinitz, M., Unger, P., and Mellstedt, H. (1991) Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1): an important antitumoral effector function?Hybridoma 10, 421–432.

    PubMed  Google Scholar 

  17. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., Mc Pherson, K., Peto, J., and Smith, P. G. (1977) Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples.Br. J. Cancer 35, 1–39.

    PubMed  CAS  Google Scholar 

  18. Kalbfleisch, J. D. and Prentice, R. L. (1980) Time dependent covariates and further remarks on likelihood construction, inThe Statistical Analysis of Failure Time Data, 1st ed., Kalbfleisch, J. D. and Prentice, R. L., eds.), Wiley, New York, pp. 122–142.

    Google Scholar 

  19. Enterline, P. E. (1976) Pitfalls in epidemiological research: an examination of asbestos literature.J. Occup. Med. 18, 150–156.

    Article  PubMed  CAS  Google Scholar 

  20. Shawler, D. L., Bartholomew, R. M., Smith, L. M., and Dillman, R. O. (1985) Human immune response to multiple injections of murine monoclonal IgG.J. Immunol. 135, 1530–1535.

    PubMed  CAS  Google Scholar 

  21. Frodin, J.-E., Lefvert, A.-K., and Mellstedt, H. (1990) Pharmacokinetics of the mouse monoclonal antibody 17-1A in cancer patients receiving various treatment schedules.Cancer Res. 50, 4866–4871.

    PubMed  CAS  Google Scholar 

  22. Mannik, M., Arend, W. P., Hall, A. P., and Gilliland, B. C. (1971) Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation.J. Exp. Med. 133, 713–739.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology (Radiumhemmet), Karolinska Hospital, Stockholm, Sweden

    Jan-Erik Frödin & Håkan Mellstedt

  2. Immunological Research Laboratory, Karolinska Hospital, Stockholm, Sweden

    Jan-Erik Frödin, Ann-Kari Lefvert & Håkan Mellstedt

Authors
  1. Jan-Erik Frödin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann-Kari Lefvert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Håkan Mellstedt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frödin, JE., Lefvert, AK. & Mellstedt, H. The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophysics 21, 153–165 (1992). https://doi.org/10.1007/BF02789485

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02789485

Keywords

Search

Navigation